McKesson debuts Wellverse name for Medical-Surgical Solutions business

IRVING, Texas – McKesson has announced Wellverse is the new name of the future standalone McKesson Medical-Surgical Solutions business.

As part of its fiscal year 2027 first quarter financial results, the company also noted that on June 9 it established a secured Term Loan B facility of $2.25 billion in support of the planned separation of the business. Previously, it sold an approximately 13% minority interest in the business to Apollo Funds for $1.25 billion.

“This represents an important milestone in our journey toward becoming an independent company,” said Stanton McComb, president, McKesson Medical-Surgical. “The Wellverse name speaks to our purpose as a company: Delivering a future where health care providers and patients thrive.”

Wellverse will continue to offer a broad portfolio of medical products, distribution services, inventory and business management tools, and personalized support to health care providers across care settings, including physician offices, health systems, laboratories, and home health.

McKesson provided the following results for the Medical-Surgical business for the first quarter:

• Revenues were $2.8 billion, an increase of 4%, driven by growth across alternate sites of care, led by higher volumes of specialty pharmaceuticals
• Operating profit was $122 million and adjusted segment operating profit was $195 million, a decrease of 20%, driven by product mix and one-time administrative expenses, partially offset by contributions from the extended care channel

For the full company:

• Consolidated revenues of $105.4 billion increased 8%.
• Earnings per diluted share of $5.15 decreased $1.10.
• Adjusted Earnings per Diluted Share of $9.93 increased 20%.

“McKesson delivered a strong start to fiscal 2027, underscored by momentum across the enterprise and disciplined execution against our strategic priorities,” said Brian Tyler, chair and CEO. “Our first quarter performance exceeded our expectations, highlighted by 20% growth in adjusted earnings per diluted share. It demonstrates the strength of our core distribution businesses, continued growth in oncology and multispecialty, and solid execution across our biopharma services platform.”

• Related: McKesson moves Medical-Surgical Solutions closer to IPO.

Photo courtesy of McKesson.